Business Description
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas. The company focuses on developing therapies for difficult-to-treat cancers by targeting biological pathways that promote tumor growth and resistance. Its lead product candidate, elraglusib, is a small-molecule inhibitor currently in clinical trials for metastatic pancreatic cancer and various pediatric malignancies.
Everything on Actuate Therapeutics, Inc.
Financials
View financials ↗
YoY growth
—
Operating margin
—
Direction
—
Gross margin
—
Net margin
—
Leadership & board
View leadership ↗
Daniel Schmitt — President, Chief Executive Officer & Director
View full profile ↗
Andrew Mazar — Chief Operating Officer
View full profile ↗
Paul Lytle — Chief Financial Officer
View full profile ↗
Aaron Fletcher — Chairperson & Director
View full profile ↗
Jason Keyes — Director
View full profile ↗
Amy Ronneberg — Director
View full profile ↗
Roger Sawhney — Director
View full profile ↗
Todd Thomson — Director
View full profile ↗
Dan Zabrowski — Director
View full profile ↗
Earnings
View all quarters ↗Named Competitors
Revolution Medicines, Inc.Arcus Biosciences, Inc.IpsenAstellasPanbela Therapeutics, Inc.Immuneering CorporationLisata TherapeuticsTheriva BiologicsOncolytics BiotechAlligator Bioscience
Customer Concentration
Actuate Therapeutics is a pre-revenue, clinical-stage biopharmaceutical company with no products approved for sale and no product revenue to date; accordingly, it has no commercial customers or customer concentration.
Recent SEC Filings
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.